Insider Transactions in Q1 2021 at Avantor, Inc. (AVTR)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 09
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Open market or private sale
|
Direct |
10,000
-3.94%
|
$280,000
$28.21 P/Share
|
|
Mar 02
2021
|
Michael Wondrasch EVP & CIO |
SELL
Open market or private sale
|
Direct |
3,036
-2.04%
|
$85,008
$28.71 P/Share
|
|
Feb 25
2021
|
Gerard Brophy EVP, Biopharma Production |
BUY
Grant, award, or other acquisition
|
Direct |
16,281
+7.94%
|
-
|
|
Feb 25
2021
|
Mark Christopher Murray EVP, Biomaterials & AT |
BUY
Grant, award, or other acquisition
|
Direct |
8,140
+29.35%
|
-
|
|
Feb 25
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
BUY
Grant, award, or other acquisition
|
Direct |
16,281
+6.03%
|
-
|
|
Feb 25
2021
|
Michael Wondrasch EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
8,140
+5.2%
|
-
|
|
Feb 25
2021
|
Justin Miller EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,140
+6.28%
|
-
|
|
Feb 25
2021
|
Thomas A Szlosek EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
16,281
+5.63%
|
-
|
|
Feb 25
2021
|
Meghan Henson EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,140
+23.91%
|
-
|
|
Feb 25
2021
|
Devashish Ohri EVP, IMEA |
BUY
Grant, award, or other acquisition
|
Direct |
5,427
+3.36%
|
-
|
|
Feb 25
2021
|
James Bramwell EVP Sales, Customer Excellence |
BUY
Grant, award, or other acquisition
|
Direct |
5,427
+4.3%
|
-
|
|
Feb 25
2021
|
Rakesh Sachdev Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+18.06%
|
-
|
|
Feb 25
2021
|
Christophe Couturier EVP, AMEA |
BUY
Grant, award, or other acquisition
|
Direct |
6,784
+3.86%
|
-
|
|
Feb 25
2021
|
Michael Stubblefield President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
72,359
+4.57%
|
-
|
|
Feb 25
2021
|
Sven Henrichwark EVP, APAC Region |
BUY
Grant, award, or other acquisition
|
Direct |
5,427
+21.51%
|
-
|
|
Feb 25
2021
|
Michael Severino Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+29.54%
|
-
|
|
Feb 25
2021
|
Sheri Lewis EVP, Global Ops & Supply Chain |
BUY
Grant, award, or other acquisition
|
Direct |
13,567
+16.87%
|
-
|
|
Feb 25
2021
|
Rajiv Gupta Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+0.5%
|
-
|
|
Feb 25
2021
|
Christi Shaw Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+28.06%
|
-
|
|
Feb 25
2021
|
Gregory L Summe Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+32.81%
|
-
|
|
Feb 25
2021
|
Juan Andres Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+24.59%
|
-
|
|
Feb 25
2021
|
Jonathan M Peacock Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+4.12%
|
-
|
|
Feb 25
2021
|
Steven W Eck SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,151
+16.09%
|
-
|
|
Feb 24
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
3,059
-1.74%
|
$82,593
$27.93 P/Share
|
|
Feb 24
2021
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,577
-9.03%
|
$69,579
$27.94 P/Share
|
|
Feb 24
2021
|
Steven W Eck SVP & Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,550
+23.06%
|
-
|
|
Feb 22
2021
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,980
-1.15%
|
$83,440
$28.69 P/Share
|
|
Feb 22
2021
|
Devashish Ohri EVP, IMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,210
-0.8%
|
$33,880
$28.69 P/Share
|
|
Feb 22
2021
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Payment of exercise price or tax liability
|
Direct |
1,216
-1.04%
|
$34,048
$28.69 P/Share
|
|
Feb 22
2021
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,141
-0.7%
|
$283,948
$28.69 P/Share
|
|
Feb 22
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-0.17%
|
$11,144
$28.69 P/Share
|
|
Feb 22
2021
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
449
-2.2%
|
$12,572
$28.69 P/Share
|
|
Feb 22
2021
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,350
-1.18%
|
$37,800
$28.69 P/Share
|
|
Feb 22
2021
|
Michael Wondrasch EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,209
-0.85%
|
$33,852
$28.69 P/Share
|
|
Feb 22
2021
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,313
-0.8%
|
$36,764
$28.69 P/Share
|
|
Feb 22
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
19,769
-10.13%
|
$553,532
$28.62 P/Share
|
|
Feb 22
2021
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
19,769
+9.2%
|
$336,073
$17.67 P/Share
|
|
Feb 22
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
3,072
-1.72%
|
$86,016
$28.69 P/Share
|
|
Feb 05
2021
|
Michael Wondrasch EVP & CIO |
SELL
Open market or private sale
|
Direct |
49,468
-14.15%
|
$1,434,572
$29.77 P/Share
|
|
Feb 05
2021
|
Michael Wondrasch EVP & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+18.06%
|
$920,000
$23.2 P/Share
|
|
Jan 13
2021
|
Mark Christopher Murray EVP, Biomaterials & AT |
SELL
Payment of exercise price or tax liability
|
Direct |
918
-7.42%
|
$26,622
$29.2 P/Share
|
|
Jan 11
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
378,580
-51.2%
|
$11,357,400
$30.06 P/Share
|
|
Jan 11
2021
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
378,580
+33.83%
|
$8,707,340
$23.2 P/Share
|
|
Jan 11
2021
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Open market or private sale
|
Direct |
2,505
-2.11%
|
$75,150
$30.0 P/Share
|
|
Jan 06
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
11,509
-6.06%
|
$310,743
$27.24 P/Share
|
|
Jan 04
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
59,418
-23.82%
|
$1,604,286
$27.84 P/Share
|
|
Jan 04
2021
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
59,418
+19.24%
|
$1,069,524
$18.45 P/Share
|
|
Jan 02
2021
|
Michael Wondrasch EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,083
-2.65%
|
$114,324
$28.15 P/Share
|
|
Jan 02
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-0.43%
|
$28,476
$28.15 P/Share
|
|
Jan 02
2021
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,135
-3.06%
|
$227,780
$28.15 P/Share
|